	US 12,240,905 B2
	Antibodies binding CTLA-4 and uses thereof
Xin Gan, Shanghai (CN); Yun He, Shanghai (CN); Yuqiang Shen, Shanghai (CN); Jiuqiao Zhao, Newton, MA (US); Yiping Rong, Shanghai (CN); Frank Grosveld, Rotterdam (NL); Dubravka Drabek, Rotterdam (NL); Marinus (Rien) Van Haperen, Prinsenbeek (NL); and Rick Janssens, Rotterdam (NL)
Assigned to Harbour BioMed (Shanghai) Co., Ltd., Shanghai (CN)
Filed by Harbour BioMed (Shanghai) Co., Ltd., Shanghai (CN)
Filed on Jul. 14, 2021, as Appl. No. 17/375,940.
Application 17/375,940 is a division of application No. 16/224,825, filed on Dec. 19, 2018, granted, now 11,098,122.
Claims priority of provisional application 62/607,917, filed on Dec. 20, 2017.
Prior Publication US 2022/0002414 A1, Jan. 6, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

20 Claims

1. A method of treating a disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an isolated monoclonal antibody or an antigen-binding portion thereof comprising a CD152-binding domain, and a pharmaceutical acceptable excipient,

wherein the CD152-binding domain comprises an immunoglobulin heavy chain variable region comprising CDR1, CDR2, and CDR3,

wherein the CDR1, CDR2, and CDR3 comprise amino acid sequences of

(1) SEQ ID NOs: 4, 5 and 6, respectively;

(2) SEQ ID NOs: 10, 11 and 12, respectively;

(3) SEQ ID NOs: 16, 17 and 18, respectively;

(4) SEQ ID NOs: 22, 23 and 24, respectively;

(5) SEQ ID NOs: 28, 29 and 30, respectively;

(6) SEQ ID NOs: 34, 35 and 36, respectively;

(7) SEQ ID NOs: 40, 41 and 42, respectively;

(8) SEQ ID NOs: 46, 47 and 48, respectively;

(9) SEQ ID NOs: 52, 53 and 54, respectively;

(10) SEQ ID NOs: 58, 59 and 60, respectively;

(11) SEQ ID NOs: 64, 65 and 66, respectively;

(12) SEQ ID NOs: 94, 95 and 96, respectively;

(13) SEQ ID NOs: 100, 101 and 102, respectively; or

(14) SEQ ID NOs: 184, 185 and 186, respectively; and

wherein the disorder is a cancer or an autoimmune disease.